Flavonoids, Blood Pressure and Blood Vessel Function

NCT ID: NCT01530893

Last Updated: 2014-02-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-29

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary aim of this placebo-controlled study is to determine whether flavonoids beneficially affect markers of cardiovascular disease risk in healthy subjects at elevated cardiovascular risk.

The underlying mechanisms of action of flavonoids will be assessed on blood biomarkers and we will assess the effects of the food matrix, and aspects of isoflavone metabolism.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study population will be healthy males (aged 50-75 years) at elevated risk of cardiovascular (CV) disease.

A target of 60 participants will be required to complete the study and a total of 70 subjects will be targeted (n=70 subjects \* \~85% anticipated completion rate = 60 subjects to complete the study).

This placebo-controlled study will test the relative efficacy of 4 different flavonoid sub-classes ((i) flavan-3-ol, (ii) anthocyanin, (iii) flavanone and (iv) isoflavone).

Accordingly, subjects will be randomised to one of the four flavonoid study groups ((i) to (iv) outlined above), and then will consume each of the following treatments in random order:

1. dietary flavonoid + placebo supplement
2. placebo food + commercially available/produced flavonoid supplement
3. placebo food + placebo supplement

Additionally, an isoflavone metabolite will be fed to establish potential vascular effects.

Each sub-class will be assessed separately and a 1 week wash-out period between treatments will be observed.

At each assessment visit, vascular function will be assessed pre- and post-intervention, with subsequent assessments made to coincide with anticipated peak plasma concentrations.

Dietary intake will be monitored during the study and participants will be required to adhere to a range of dietary and lifestyle restrictions within 3 days of each assessment to reduce potential confounding of the data assessment of interest.

A standard battery of vascular function tests will be performed on all intervention groups, with each assessment visit performed in an identical manner.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Disease Risk Reduction

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

flavonoids vascular function randomised controlled trial placebo controlled

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group A: flavanones

All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.

Group Type EXPERIMENTAL

Flavanone - supplement

Intervention Type DIETARY_SUPPLEMENT

acute single optimal dose

Flavanone - food

Intervention Type OTHER

acute single dose

Flavanone - placebo

Intervention Type OTHER

acute single dose (flavanone free)

Intervention group B: isoflavones

All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.

Group Type EXPERIMENTAL

Isoflavone - supplement

Intervention Type DIETARY_SUPPLEMENT

acute single optimal dose

Isoflavone - food

Intervention Type OTHER

acute single optimal dose

Isoflavone - placebo

Intervention Type OTHER

acute single dose (isoflavone free)

Isoflavone - metabolite supplement

Intervention Type DIETARY_SUPPLEMENT

acute single optimal dose of commercial product

Intervention group C: Flavan-3-ols

All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.

Group Type EXPERIMENTAL

Flavan-3-ol - supplement

Intervention Type DIETARY_SUPPLEMENT

acute single optimal dose

Flavan-3-ol - food

Intervention Type OTHER

acute single optimal dose

Flavan-3-ol - placebo

Intervention Type OTHER

acute single dose (flavan-3-ol free)

Intervention group D: Anthocyanins

All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.

Group Type EXPERIMENTAL

Anthocyanin - supplement

Intervention Type DIETARY_SUPPLEMENT

acute single optimal dose

Anthocyanin - food

Intervention Type OTHER

acute single optimal dose

Anthocyanin - placebo

Intervention Type OTHER

acute single dose (anthocyanin free)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Flavanone - supplement

acute single optimal dose

Intervention Type DIETARY_SUPPLEMENT

Flavanone - food

acute single dose

Intervention Type OTHER

Flavanone - placebo

acute single dose (flavanone free)

Intervention Type OTHER

Isoflavone - supplement

acute single optimal dose

Intervention Type DIETARY_SUPPLEMENT

Isoflavone - food

acute single optimal dose

Intervention Type OTHER

Isoflavone - placebo

acute single dose (isoflavone free)

Intervention Type OTHER

Isoflavone - metabolite supplement

acute single optimal dose of commercial product

Intervention Type DIETARY_SUPPLEMENT

Flavan-3-ol - supplement

acute single optimal dose

Intervention Type DIETARY_SUPPLEMENT

Flavan-3-ol - food

acute single optimal dose

Intervention Type OTHER

Flavan-3-ol - placebo

acute single dose (flavan-3-ol free)

Intervention Type OTHER

Anthocyanin - supplement

acute single optimal dose

Intervention Type DIETARY_SUPPLEMENT

Anthocyanin - food

acute single optimal dose

Intervention Type OTHER

Anthocyanin - placebo

acute single dose (anthocyanin free)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males
* 50 to 75 years old
* At elevated risk of CV disease
* Screening blood pressure of \< 160/90mmHg (at rest)
* Successful biochemical, haematological and urinalysis assessment at screening (as judged by clinical advisor)

Exclusion Criteria

* Current smokers, or ex-smokers ceasing \< 3 months ago
* Subjects with existing or significant past medical history of vascular disease or medical conditions likely to affect the study measures (as judged by clinical advisor)
* Those with known allergies to the intervention treatments
* Those unprepared to adhere to dietary restrictions during the trial
* Parallel participation in another research project which involves concurrent dietary intervention and/or sampling of biological fluids/material
* Having vaccinations (excluding the flu vaccination) or antibiotics within 3 months of start of trial, and those with vaccinations scheduled for during the trial
* Taking flavonoid containing food / dietary supplements likely to affect the study results
* Prescribed lipid lowering, hypertension, vasodilators (e.g. Viagra) or antibiotic medication
* Unsatisfactory biochemical, haematological or urinary assessment at screening, indicating abnormal; renal or liver function, full blood profile, impaired glucose handling, deranged lipids or measurements considered to be counter indicative of the study by the clinical advisor
Minimum Eligible Age

50 Years

Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of East Anglia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Aedin Cassidy, PhD

Role: PRINCIPAL_INVESTIGATOR

University of East Anglia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Nutrition, Norwich Medical School

Norwich, Norfolk, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Hazim S, Curtis PJ, Schar MY, Ostertag LM, Kay CD, Minihane AM, Cassidy A. Acute benefits of the microbial-derived isoflavone metabolite equol on arterial stiffness in men prospectively recruited according to equol producer phenotype: a double-blind randomized controlled trial. Am J Clin Nutr. 2016 Mar;103(3):694-702. doi: 10.3945/ajcn.115.125690. Epub 2016 Feb 3.

Reference Type DERIVED
PMID: 26843154 (View on PubMed)

Schar MY, Curtis PJ, Hazim S, Ostertag LM, Kay CD, Potter JF, Cassidy A. Orange juice-derived flavanone and phenolic metabolites do not acutely affect cardiovascular risk biomarkers: a randomized, placebo-controlled, crossover trial in men at moderate risk of cardiovascular disease. Am J Clin Nutr. 2015 May;101(5):931-8. doi: 10.3945/ajcn.114.104364. Epub 2015 Mar 18.

Reference Type DERIVED
PMID: 25788001 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FASTCHECK

Identifier Type: -

Identifier Source: org_study_id